Demographic data of patients with and without hallucinations
| None | Visual only | Visual and auditory | |
|---|---|---|---|
| n | 76 | 35 | 10 |
| Age (y) | 74 (9) | 74 (7) | 74 (9) |
| SMT (%) | 90 (9) | 80 (3) * | 80 (2)‡ |
| Cognitively impaired (%) | 25 | 64† | 50 |
| Duration of disease (y) | 7 (6) | 8 (4) | 6 (5) |
| Time on levodopa (y) | 4 (4) | 7 (5)‡ | 6 (5)‡ |
| Hoehn and Yahr stage (I/II/III) | 2/23/51 | 0/8/27 | 0/0/10 |
Values in parentheses are SD.
The short mental scores (SMT) were lower in patients with visual ( * p<0.001) and auditory (‡0.05<p<0.1) hallucinations than in those without. The percentage of patients with cognitive impairment was significantly higher among those with visual hallucinations than among those without (†p<0.01). The duration of levodopa treatment was minimally longer in patients with hallucinations than in those without (‡0.05<p<0.1). The proportion of patients at stage III was minimally higher among patients with auditory hallucinations than among those without (‡0.05<p<0.1).